Ortho Molecular Products and Calocurb® Reveal New Appetite Control Solution for Licensed Practitioners

New Appetite Management Solution Unveiled

In an exciting development for healthcare practitioners, Ortho Molecular Products has joined forces with New Zealand's Calocurb® to introduce Calocurb® CLINICAL. This new addition, launching in October 2025, presents a clinically-backed, plant-based solution to appetite management, aimed specifically at professionals in the health sector looking to better support their clients' nutritional needs.

The Alliance

Ortho Molecular Products has established itself as a key player in the nutraceutical industry, catering exclusively to licensed healthcare professionals. This collaboration allows them to distribute Calocurb® CLINICAL, a supplement designed to address appetite and cravings through a scientifically validated approach.

The heart of Calocurb® CLINICAL lies in its active ingredient, Amarasate®, a natural extract derived from a specific bitter hop. This revolutionary compound has undergone extensive research, supported by a $20 million investment from the New Zealand government, leading to successful outcomes in four human clinical trials.

How It Works

Calocurb® CLINICAL delivers a 250 mg dose of Amarasate®, effectively targeting bitter taste receptors in the gut. Upon reaching the small intestine, Amarasate® prompts the secretion of key satiety hormones, including GLP-1, CCK, and PYY. These hormones play crucial roles in regulating hunger, cravings, and overall metabolic health.

Nate Freeman, Vice President of Science and Innovation at Ortho Molecular Products, emphasized the commitment to scientific efficacy, stating: "In every product and partnership, we start with the question, 'Does it work?' Our focus is on fostering better patient outcomes through understanding cravings and satiety. This product acts almost as a shield for those struggling with emotional eating and cravings, empowering practitioners to provide better support to their patients."

Clinical Results

Calocurb® CLINICAL has demonstrated impressive efficacy in clinical evaluations. Studies reveal that participants experienced a significant reduction in hunger by 30%, cravings by 40%, and caloric intake by 18% within just one hour after consumption. This rapid action is attributed to the activation of bitter taste receptors by Amarasate®, which effectively enhances the body's natural satiety signals, leading to feelings of fullness sooner.

Goals for Practitioners

The primary aim of the partnership between Ortho Molecular Products and Calocurb® is to provide healthcare practitioners with reliable tools they need to assist their patients in managing their food relationships and promoting lasting wellness. As Sarah Kennedy, CEO of Calocurb®, noted, "Our mission aligns with Ortho Molecular’s commitment to scientific development. By working together, we ensure that practitioners have ready access to innovative solutions like Calocurb® CLINICAL, guided by a knowledgeable support team."

Looking Forward

Calocurb® CLINICAL is set to be an exclusive offering for licensed healthcare practitioners, starting from October 2025. This partnership underscores the importance of clinically validated products and their potential to transform patient care in the realm of appetite control and metabolic health.

For over 35 years, Ortho Molecular Products has stood out in the industry, providing high-quality nutraceuticals primarily sold to healthcare professionals across the U.S. and Canada. Their unwavering focus on efficacy and quality manufacturing establishes them as a leader in the nutritional supplement market.

In summary, the launch of Calocurb® CLINICAL represents a significant advancement in appetite management solutions, tailored for the healthcare community. With proven results and a commitment to science, this partnership aims to equip practitioners to better support their patients in achieving effective and sustainable dietary control.